AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01028326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV10 and DTaP
Description: A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
Study NCT01028326 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine, DTaP, PCV10
Description: A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
Study NCT01903291 — intervention group
Intervention type: DRUG
Intervention: dimethyl fumarate
Description: As described in the treatment arm
Study NCT00637975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops.
Study NCT00637975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops.
Study NCT01034332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TP-HDFL,TP-CCRT, Esophagectomy
Description: To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
Study NCT03288103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin
Description: Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
Study NCT03405597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial Hepatitis B vaccine
Description: Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
Study NCT04553510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and steroid
Description: Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
Study NCT04553510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab and placebo
Description: Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
Study NCT00393952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/Formoterol fumarate 250/10
Description: FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT00393952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
Study NCT00393952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/Formoterol fumarate 100/10
Description: FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT00393952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250
Description: Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT00393952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumarate 10
Description: Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study NCT03827772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: 30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
Study NCT03827772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care treatment
Description: Nutritional supplementation, supportive management.
Study NCT02193048 — intervention group
Intervention type: OTHER
Intervention: This study will evaluate a new clinical scoring system in patients receiving routine treatment
Description: Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
Study NCT03898492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical training
Description: Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
Study NCT02000427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
Study NCT04759261 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SMAD4 expression and methylation
Description: Effect of SMAD4 methylations on smad4 expression
Study NCT03359525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: intravenous versus Intraarticular versus intravenous
Study NCT03497806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP101
Description: Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
Study NCT02380950 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 250 ml alcohol consumption
Description: Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510.
Study NCT01955447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no added plant-based ingredients to starchy meal
Description: no added plant-based ingredients to starchy meal
Study NCT01955447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low level plant-based ingredients added to starchy meal
Description: Low level plant-based ingredients added to starchy meal
Study NCT01955447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medium level plant-based ingredients added to starchy meal
Description: Medium level plant-based ingredients added to starchy meal
Study NCT01955447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High level plant-based ingredients added to starchy meal
Description: High level plant-based ingredients added to starchy meal
Study NCT00475722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1 Healthy Eating
Description: 6 months telephone counseling
Study NCT00475722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Mediterranean
Description: 6 months telephone counseling
Study NCT01395251 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: prednisolone 20 mg once a day per os for 3 subsequent days
Study NCT03128970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synchronizing blastocysts
Description: transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.
Study NCT02495220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB dexmedetomidine bupivacaine block
Description: SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
Study NCT02495220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous dexmedetomidine
Description: received 1µ/kg IV dexmedetomidine
Study NCT02762279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: esophageal and pleural pressure measurement
Description: Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
Study NCT02882490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Study NCT02882490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Therapy
Study NCT02895503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participate in yoga
Study NCT02895503 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group Therapy
Description: Participate in emotional support group therapy
Study NCT02895503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-L
Description: This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, \& Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
Study NCT02895503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FACT-L
Description: This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, \& Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
Study NCT02895503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary function test
Description: The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
Study NCT02895503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary function test
Description: The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
Study NCT02920424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56022473
Description: Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
Study NCT02920424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo.
Study NCT01130051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg tablet
Description: One Colcrys® 0.6 mg intact tablet taken by mouth
Study NCT01130051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg tablet
Description: One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
Study NCT04687813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with the same appearance as FTP-198
Study NCT02848950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Supplementation of the study group with Metformin till the day of pregnancy confirmation
Study NCT02807649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Nutrilite® Low dose
Description: Two tablets consume daily with meal.
Study NCT02807649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Nutrilite® High dose
Description: Two tablets consume daily with meal.
Study NCT02807649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Two tablets consume daily with meal.
Study NCT00851123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement therapy
Description: Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
Study NCT00851123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-specific bimanual training
Description: Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
Study NCT03715088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Intervention
Description: Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.
Study NCT02747953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilotrif
Description: 50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
Study NCT06363669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-ingredient pre-workout dietary supplement (caffeine-based)
Description: The participants performed the exercise twice, in random order: as a control test and after supplement administration. The acute effects of MIPS supplementation (beta-alanine 3000 mg, taurine 1000 mg, caffeine 290 mg, L-tyrosine 125 mg, and cayenne pepper extract (Capsicum annuum L.) 4.2 mg (of which 8% capsaicin)) on aerobic and anaerobic performance were evaluated in untrained men
Study NCT01335009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MORAb-004 (monoclonal antibody)
Description: Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
Study NCT04196738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation strategy
Description: Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation
Study NCT01169220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Go-Lytely
Description: Bowel cleansing agent
Study NCT01169220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Go Lytely
Description: Bowel cleansing agent
Study NCT02954939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF-MMF
Description: Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
Study NCT02954939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTX-AZA
Description: Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
Study NCT03405597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
Study NCT06734806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic Imaging and Digital STL Analysis
Description: This study utilizes radiographic imaging (bitewing radiographs) and digital analysis of archived STL files to evaluate the clinical performance of endocrown and overlay restorations. The STL files are processed using Materialise 3-matic software to calculate cemented surface areas. Radiographic imaging assesses the presence of secondary caries or other failures. These diagnostic methods provide quantitative and visual data to evaluate long-term outcomes of the restorations.
Study NCT06734806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FDI Criteria Evaluation and Plaque Index Measurement
Description: This intervention includes the evaluation of dental restorations using modified FDI criteria, assessed on a 5-point Likert scale that measures aesthetic, functional, and biological outcomes. Additionally, oral hygiene is assessed through the measurement of the plaque index, with a mean score calculated for each participant. The use of both FDI-based Likert scoring and plaque index measurements allows for a detailed evaluation of restoration performance and oral health status, combining subjective patient-reported outcomes with objective clinical metrics.
Study NCT02901925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-029
Description: Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
Study NCT01264653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenalin
Description: adrenalin 0.01%
Study NCT03405597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
Study NCT03116412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT or PET scans
Description: Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
Study NCT02428010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMVR Implant
Description: Implantation of the Twelve TMVR System
Study NCT05762523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC∆6 vaccine - оnce at a dose of 10⁶ PFU
Description: 15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
Study NCT05762523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC∆6 vaccine - once at a dose of 10⁷ PFU
Description: 15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
Study NCT05762523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC∆6 vaccine - twice at a dose of 10⁶ PFU
Description: 15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
Study NCT05762523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine
Description: 15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
Study NCT00332839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
Study NCT00332839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A (CsA)
Description: The dose was based on the participants' blood level of C0h (80-150 ng/ml).
Study NCT00332839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: The dose was based on the participants' blood level of C0h (5-10 ng/ml).
Study NCT00332839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated - Mycophenolate Sodium (EC-MPS)
Description: The dose was ≥ 720 mg/day.
Study NCT00332839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated - Mycophenolate Sodium (EC-MPS)
Description: The dose was ≥ 720 mg/day.
Study NCT00332839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids were given according to local standard and/or the Investigators' discretion.
Study NCT00332839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids were given according to local standard and/or the Investigators' discretion.